Rho‑associated kinase inhibitor, Y‑27632, inhibits the invasion and proliferation of T24 and 5367 bladder cancer cells

Jiang,Lei; Wen,Jiaming; Luo,Wei

doi:10.3892/mmr.2015.4404

Rho‑associated kinase inhibitor, Y‑27632, inhibits the invasion and proliferation of T24 and 5367 bladder cancer cells

Authors:
- Lei Jiang
- Jiaming Wen
- Wei Luo
View Affiliations

Affiliations: Department of Emergency, The Fourth Affiliated Hospital of Zhejiang University School of Medicine, Yiwu, Zhejiang 322000, P.R. China, Department of Urology, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang 310009, P.R. China
Published online on: September 30, 2015 https://doi.org/10.3892/mmr.2015.4404
Pages: 7526-7530

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The serine/threonine kinases, Rho‑associated protein kinase I and II (ROCK I and II), regulate the cytoskeleton by acting downstream of the small GTPase, Rho, and have been implicated in tumorigenesis and cancer metastasis. Inhibition of ROCK signaling has been shown to suppress the invasion and migration of several types of cancer cells. In this study, the effect of the ROCK inhibitor, Y‑27632, on the proliferation and invasion of T24 and 5637 bladder cancer cells was investigated. In the proliferation assays, the cells were exposed to 0, 10, 25, 50, 75, 100, 125 or 150 µmol/l Y‑27632 and proliferation was determined using Cell Counting kit‑8 after 24, 48 and 72 h. In the invasion assays, the cells were placed in the upper chamber of transwell plates and subjected to 0, 25, 50 or 75 µmol/l Y‑27632 for 24 h, after which invasion was measured. Y‑27632 significantly suppressed the cell proliferation of T24 and 5637 cells in a concentration- and time‑dependent manner. Y‑27632 also inhibited the invasion of T24 and 5637 cells in a concentration‑dependent manner (P<0.001). In addition, Y‑27632 suppressed myosin light chain kinase (MLCK) phosphorylation in T24 and 5637 cells, confirming that it is also a downstream effector of the Rho/ROCK pathway in T24 and 5637 bladder cancer cells. In conclusion, the Rho/ROCK/P‑MLCK pathway may be important in tumor cell metastasis in bladder cancer.

View Figures

View References

1	Burger M, Catto JW, Dalbagni G, Grossman HB, Herr H, Karakiewicz P, Kassouf W, Kiemeney LA, La Vecchia C, Shariat S and Lotan Y: Epidemiology and risk factors of urothelialbladder cancer. Eur Urol. 63:234–241. 2013. View Article : Google Scholar
2	Ferreccio C, Yuan Y, Calle J, Benítez H, Parra RL, Acevedo J, Smith AH, Liaw J and Steinmaus C: Arsenic, tobacco smoke and occupation: Associations of multiple agents with lung and bladder cancer. Epidemiology. 24:898–905. 2013. View Article : Google Scholar : PubMed/NCBI
3	Chavan S, Bray F, Lortet-Tieulent J, Goodman M and Jemal A: International variations in bladder cancer incidence and mortality. Eur Urol. 66:59–73. 2014. View Article : Google Scholar : PubMed/NCBI
4	Somlyo AP and Somlyo AV: Ca²⁺ sensitivity of smooth muscle and nonmuscle myosin II: Modulated by G proteins, kinases and myosin phosphatase. Physiol Rev. 83:1325–1358. 2003. View Article : Google Scholar : PubMed/NCBI
5	Hall A: Rho GTPases and the actin cytoskeleton. Science. 279:509–514. 1998. View Article : Google Scholar : PubMed/NCBI
6	Gómez del Pulgar T, Benitah SA, Valerón PF, Espina C and Lacal JC: Rho GTPase expression in tumourigenesis: Evidence for a significant link. Bioessays. 27:602–613. 2005. View Article : Google Scholar : PubMed/NCBI
7	Matsui T, Amano M, Yamamoto T, Chihara K, Nakafuku M, Ito M, Nakano T, Okawa K, Iwamatsu A and Kaibuchi K: Rho-associated kinase, a novel serine/threonine kinase, as a putative target for small GTP binding protein Rho. EMBO J. 15:2208–2216. 1996.PubMed/NCBI
8	Duan WG, Yuan ST, Liao H, Yan M and Zhang LY: Advances in the study of Rho kinase and its inhibitors. Yao Xue Xue Bao. 42:1013–1022. 2007.In Chinese.
9	Itoh K, Yoshioka K, Akedo H, Uehata M, Ishizaki T and Narumiya S: An essential part for Rho-associated kinase in the transcellular invasion of tumor cells. Nat Med. 5:221–225. 1999. View Article : Google Scholar : PubMed/NCBI
10	Imamura F, Mukai M, Ayaki M and Akedo H: Y-27632, an inhibitor of rhoassociated protein kinase, suppresses tumor cell invasion via regulation of focal adhesion and focal adhesion kinase. Jpn J Cancer Res. 91:811–816. 2000. View Article : Google Scholar : PubMed/NCBI
11	Volanis D, Zaravinos A, Kadiyska T, Delakas D, Zoumpourlis V and Spandidos DA: Expression profile of Rho kinases in urinary bladder cancer. J BUON. 16:511–521. 2011.PubMed/NCBI
12	Abe H, Kamai T, Hayashi K, Anzai N, Shirataki H, Mizuno T, Yamaguchi Y, Masuda A, Yuki H, Betsunoh H, et al: The Rho-kinase inhibitor HA-1077 suppresses proliferation/migration and induces apoptosis of urothelial cancer cells. BMC Cancer. 14:4122014. View Article : Google Scholar : PubMed/NCBI
13	von Dorp F, Sanders H, Boergermann C, Lümmen G, Rübben H, Jakobs KH and Schmidt M: Inhibition of Rho-kinase abrogates migration of human transitional cell carcinoma cells: Results of an in vitro study. Urol Int. 86:220–227. 2011. View Article : Google Scholar
14	Ueno K, Hirata H, Majid S, Yamamura S, Shahryari V, Tabatabai ZL, Hinoda Y and Dahiya R: Tumor suppressor microRNA-493 decreases cell motility and migration ability in human bladder cancer cells by downregulating RhoC and FZD4. Mol Cancer Ther. 11:244–253. 2012. View Article : Google Scholar
15	Kamai T, Tsujii T, Arai K, Takagi K, Asami H, Ito Y and Oshima H: Significant association of Rho/ROCK pathway with invasion and metastasis of bladder cancer. Clin Cancer Res. 9:2632–2641. 2003.PubMed/NCBI
16	Rösel D, Brábek J, Tolde O, Mierke CT, Zitterbart DP, Raupach C, Bicanová K, Kollmannsberger P, Panková D, Vesely P, et al: Upregulation of Rho/ROCK signaling in sarcoma cells drives invasion and increased generation of protrusive forces. Mol Cancer Res. 6:1410–1420. 2008. View Article : Google Scholar
17	Ying H, Biroc SL, Li WW, Alicke B, Xuan JA, Pagila R, Ohashi Y, Okada T, Kamata Y and Dinter H: The Rho kinase inhibitor fasudil inhibits tumor progression in human and rat tumor models. Mol Cancer Ther. 5:2158–2164. 2006. View Article : Google Scholar : PubMed/NCBI
18	Horani A, Nath A, Wasserman MG, Huang T and Brody SL: Rho-associated protein kinase inhibition enhances airway epithelial Basal-cell proliferation and lentivirus transduction. Am J Respir Cell Mol Biol. 49:341–347. 2013. View Article : Google Scholar : PubMed/NCBI
19	Yu Z, Liu M, Fu P, Xie M, Wang W and Luo X: ROCK inhibition with Y27632 promotes the proliferation and cell cycle progression of cultured astrocyte from spinal cord. Neurochem Int. 61:1114–1120. 2012. View Article : Google Scholar : PubMed/NCBI
20	Mueller BK, Mack H and Teusch N: Rho kinase, a promising drug target for neurological disorders. Nat Rev Drug Discov. 4:387–398. 2005. View Article : Google Scholar : PubMed/NCBI
21	Huang HP, Wang CJ, Tsai JP, Wu SW, Hung TW, Lian JD and Chang HR: Y27632 attenuates the aristolochic acid-promoted invasion and migration of human urothelial cancer TSGH cells in vitro and inhibits the growth of xenografts in vivo. Nephrol Dial Transplant. 27:565–575. 2012. View Article : Google Scholar
22	Heneweer C, Kruse LH, Kindhäuser F, Schmidt M, Jakobs KH, Denker H and Thie M: Adhesiveness of human uterine epithelial RL95-2 cells to trophoblast: Rho protein regulation. Mol Hum Reprod. 8:1014–1022. 2002. View Article : Google Scholar : PubMed/NCBI
23	Fukata M, Nakagawa M and Kaibuchi K: Roles of Rho-family GTPases in cell polarisation and directional migration. Curr Opin Cell Biol. 15:590–597. 2003. View Article : Google Scholar : PubMed/NCBI
24	Song Y, Hoang BQ and Chang DD: ROCK-II-induced membrane blebbing and chromatin condensation require actin cytoskeleton. Exp Cell Res. 278:452–521. 2002. View Article : Google Scholar